Featured Research

from universities, journals, and other organizations

First Human Trial Tests Stem-cell-based Treatment For Heart Attacks

Date:
March 28, 2007
Source:
American College of Cardiology
Summary:
Previous research on the efficacy of stem cell therapy for heart repair has shown possible benefit from mesenchymal stem cells (MSCs) -- cells found in bone marrow that create connective tissue, bone and cartilage. A recent study reveals the results of the first human trial using MSCs for the treatment of myocardial infarction (MI, or heart attack).

Despite the enduring controversy surrounding the use of embryonic stem cells for disease research, scientists continue to evaluate the therapeutic potential of other types of stem cells. Previous research on the efficacy of stem cell therapy for heart repair has shown possible benefit from mesenchymal stem cells (MSCs) -- cells found in bone marrow that create connective tissue, bone and cartilage. A study presented at the American College of Cardiology's Innovation in Intervention: i2 Summit reveals the results of the first human trial using MSCs for the treatment of myocardial infarction (MI, or heart attack).

As a cell-based therapy, MSCs have a number of unique advantages: they can be taken from genetically distinct donors, are easy to prepare, and have a tendency to collect within injured areas. In animal models, MSCs not only home to regions of MI, but reduce infarct size and improve ejection fraction -- the portion of blood that is pumped out of the heart as a result of a heartbeat, and a primary indicator of the heart's health.

Researchers from ten medical centers across the United States, led by Joshua Hare, M.D., of the University of Miami, Miller School of Medicine, conducted a Phase 1 trial to assess the safety and efficacy of infusing MSCs intravenously to 53 patients within ten days of a heart attack. In the trial, patients were randomized to one of three doses: 0.5, 1.6 or 5 million MSCs/kg, and each dose was compared with placebo. The occurrence of treatment-related serious adverse events was evaluated over a six-month period, and efficacy was assessed using echocardiography.

Over the six month follow-up period, the stem cell-treated patients had lower rates of side effects such as cardiac arrhythmias, and had significant improvements in heart, lung and global function. Echocardiography showed improved heart function, particularly in those with large amounts of cardiac damage.

"This trial makes an important contribution in the field of stem cell-based treatments for heart disease by providing safety and efficacy data for a unique and promising type of stem cell to treat cardiac damage," said Joshua Hare, M.D., of the University of Miami and lead author of the study. "It's important to note that this study represents a first step, and, as in other disease categories, we must perform additional, larger trials to determine the real world application of mesenchymal stem cell therapy to fight heart disease."

Reference: Dr. Joshua Hare. "A Double-Blind, Randomized, Placebo Controlled Clinical Trial of Allogeneic Mesenchymal Stem Cells for the Treatment of Patients With Acute Myocardial Infarction" American College of Cardiology's Innovation in Intervention: i2 Summit in New Orleans, La.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "First Human Trial Tests Stem-cell-based Treatment For Heart Attacks." ScienceDaily. ScienceDaily, 28 March 2007. <www.sciencedaily.com/releases/2007/03/070326121246.htm>.
American College of Cardiology. (2007, March 28). First Human Trial Tests Stem-cell-based Treatment For Heart Attacks. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2007/03/070326121246.htm
American College of Cardiology. "First Human Trial Tests Stem-cell-based Treatment For Heart Attacks." ScienceDaily. www.sciencedaily.com/releases/2007/03/070326121246.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins